Trial Profile
Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms SHARED
- 29 Aug 2020 Results evaluating Characteristics of adults with difficult-to-treat hepatitis C virus genotype subtype 4r infection presented at The International Liver Congress 2020
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.